Compound Identity
OP-Ts is a 44-amino-acid synthetic stabilized peptide analog (MW ≈ 5,040.6 Da) of growth hormone-releasing hormone (GHRH). It features a trans-3-hexenoic acid modification at the N-terminus, which provides resistance to dipeptidyl peptidase IV (DPP-IV) degradation compared to native GHRH while retaining the full 44-amino-acid GHRH sequence.
Receptor Selectivity Profile
GHRHR (Growth Hormone-Releasing Hormone Receptor) — full agonist
Comparative receptor assays demonstrate primary selectivity toward GHRHR signaling pathways
Structural Features
Amino acid count: 44 residues
Molecular weight: ~5,040.6 Da
N-terminal modification: trans-3-hexenoic acid (DPP-IV resistance)
Structural class: Stabilized GHRH analog
Receptor class: GHRHR full agonist
Areas of Active Scientific Investigation
Receptor Pharmacology Research: Studies examining GHRHR binding affinity and agonist potency relative to native GHRH.
Structural Stability Research: Investigations into DPP-IV resistance and plasma stability conferred by N-terminal modification.
Comparative Pharmacology: Research comparing OP-Ts with native GHRH and related 44-amino-acid analogs.
Pharmacokinetic Studies: Characterization of half-life and bioavailability profiles in research models.
Regulatory & Research Context
OP-Ts is sold strictly for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or application of any kind. It is not approved by the FDA to diagnose, treat, cure, or prevent any disease or condition. Not for use in any living organism.
Scientific References
- Ferdinandi ES, et al. Basic & Clinical Pharmacology & Toxicology. 2007.
- Veldhuis JD, et al. Journal of Clinical Endocrinology & Metabolism. 2001; 86(1):298–305.
- PubMed: PMC11209896 | PMC3258893
Wholesale
